UZH-Logo

Maintenance Infos

Natriumphosphat enthaltende Darmreinigungsmittel – eine Gefahr für die Niere?


Russmann, S; Szeless, T; Bock, A; Kullak-Ublick, G A (2009). Natriumphosphat enthaltende Darmreinigungsmittel – eine Gefahr für die Niere? Swiss Medical Forum, 9(18):336-339.

Abstract

There are several well-documented cases of acute irreversible renal failure involving renal calcium phosphate deposits after the use of bowel preparations containing sodium phosphate (e.g., Colophos®).
- Neither randomised clinical nor epidemiological studies have established an
association between sodium phosphate use and renal damage in patients without preexisting renal dysfunction.
- However, it is likely that patients with preexisting renal dysfunction and other risk factors were not sufficiently represented and analysed in these studies, and may be at increased risk of (further) renal damage through sodium phosphate.
- Recommendations for clinical practice:
1. Routine determination of renal function through GFR estimation before prescription of bowel cleansing preparations containing sodium phosphate.
2. If sodium phosphate is administered, sufficient hydration is crucial: 2 L of fluids should be consumed with each 90 ml bottle of Colophos®.
3. Sodium phosphate should not be used in patients with preexisting renal dysfunction (GFR <60 ml/min), and in those with other risk factors (heart failure, concomitant use of ACE inhibitors, angiotensin receptor blockers and diuretics, preexisting dehydration and electrolyte disorders, old age). Bowel preparations containing polyethylene glycol (e.g., Cololyt®) should be given to these patients.

There are several well-documented cases of acute irreversible renal failure involving renal calcium phosphate deposits after the use of bowel preparations containing sodium phosphate (e.g., Colophos®).
- Neither randomised clinical nor epidemiological studies have established an
association between sodium phosphate use and renal damage in patients without preexisting renal dysfunction.
- However, it is likely that patients with preexisting renal dysfunction and other risk factors were not sufficiently represented and analysed in these studies, and may be at increased risk of (further) renal damage through sodium phosphate.
- Recommendations for clinical practice:
1. Routine determination of renal function through GFR estimation before prescription of bowel cleansing preparations containing sodium phosphate.
2. If sodium phosphate is administered, sufficient hydration is crucial: 2 L of fluids should be consumed with each 90 ml bottle of Colophos®.
3. Sodium phosphate should not be used in patients with preexisting renal dysfunction (GFR <60 ml/min), and in those with other risk factors (heart failure, concomitant use of ACE inhibitors, angiotensin receptor blockers and diuretics, preexisting dehydration and electrolyte disorders, old age). Bowel preparations containing polyethylene glycol (e.g., Cololyt®) should be given to these patients.

Downloads

410 downloads since deposited on 27 May 2009
43 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Clinical Pharmacology and Toxicology
Dewey Decimal Classification:610 Medicine & health
Language:German
Date:2009
Deposited On:27 May 2009 11:16
Last Modified:06 Jun 2016 12:59
Publisher:EMH Swiss Medical Publishers
ISSN:1424-3784
Free access at:Publisher DOI. An embargo period may apply.
Official URL:http://www.medicalforum.ch/pdf/pdf_d/2009/2009-18/2009-18-018.PDF
Permanent URL: https://doi.org/10.5167/uzh-18650

Download

[img]
Preview
Filetype: PDF (final manuscript)
Size: 1MB
Licence: Creative Commons: Attribution 3.0 Unported (CC BY 3.0)
[img]
Preview
Content: Published Version
Filetype: PDF
Size: 2MB

TrendTerms

TrendTerms displays relevant terms of the abstract of this publication and related documents on a map. The terms and their relations were extracted from ZORA using word statistics. Their timelines are taken from ZORA as well. The bubble size of a term is proportional to the number of documents where the term occurs. Red, orange, yellow and green colors are used for terms that occur in the current document; red indicates high interlinkedness of a term with other terms, orange, yellow and green decreasing interlinkedness. Blue is used for terms that have a relation with the terms in this document, but occur in other documents.
You can navigate and zoom the map. Mouse-hovering a term displays its timeline, clicking it yields the associated documents.

Author Collaborations